Regulatable IL-15 TIL therapy posts early responses in checkpoint-resistant melanoma
Amsokigene autoleucel, also called amsoki-cel or OBX-115, is pushing adoptive cell therapy into a more controlled biologic space. In advanced melanoma that no longer responds to immune checkpoint inhibitors, investigators pooled data from two single-arm studies to examine a tumor-infiltrating lymphocyte product engineered to express acetazolamide-regulatable membrane-bound interleukin-15, a design intended to remove the need for interleukin-2 support. The strategy is biologically elegant: T cells are expanded outside the body, then reintroduced with an internal growth signal that can be modulated rather than left to the broad, toxic stimulation of exogenous IL-2.
The first treated patient forced an immediate safety recalibration. Rapid lymphocyte expansion and vasogenic edema in a previously irradiated brain metastasis prompted protocol changes in the first-in-human study, including a substantial reduction in both the maximum amsoki-cel dose and the acetazolamide dose. That early event matters because it illustrates how aggressively infused T cells can expand in vivo when the cytokine environment is sufficient. In the brain, even a biologically intended immune surge can become clinically hazardous if local edema develops in a confined space.
Safety signals drove dose selection before efficacy could be interpreted
Across the two studies, 37 patients received treatment: 17 in the completed phase 1 single-center first-in-human study and 20 in the ongoing multicenter Agni-01 trial. After the initial de-escalation and subsequent re-escalation, the pooled analysis found no dose-limiting toxicities, no intensive care unit care and no treatment-related deaths. Those are reassuring markers for a cell therapy platform that is designed to expand after infusion, especially in a population that has already passed through checkpoint blockade and often has limited physiologic reserve.
The hematologic toxicity profile was substantial but expected in the context of lymphodepletion plus cellular therapy. The most common grade 3 or higher treatment-emergent adverse events were neutropenia in 64.9% of patients, leukopenia and lymphopenia in 56.8% each, and anemia and thrombocytopenia in 37.8% each. Serious treatment-emergent adverse events occurred in 10 patients, including eight with grade 3 or higher events; non-hematologic serious events affected 13.5% of patients and hematologic serious events affected another 13.5%. Those numbers reflect the price of creating space for transferred T cells and then sustaining their activity long enough to engage tumor burden.
Pooled efficacy signals suggest the engineered cytokine may be doing the heavy lifting
Dose selection for the recommended phase 2 dose rested on overall safety, tolerability and preliminary antitumor activity in the phase 1 portion of Agni-01. The preliminary phase 2 objective response rate at that dose was 66.7%, or 6 of 9 patients. In the 15-patient Key Efficacy Set treated at the recommended phase 2 dose, which included six patients from phase 1 and nine from phase 2, 10 patients achieved objective responses, for a response rate of 66.7% with a 95% confidence interval of 38% to 88%. Two of those responses were complete responses.
The response pattern is clinically meaningful because it emerged in immune checkpoint inhibitor-resistant melanoma, a setting where available post-ICI treatments have repeatedly fallen short. Cellular therapy can succeed where checkpoint blockade fails when the problem is not simply an exhausted endogenous immune response, but an inadequate pool of tumor-reactive effector cells that never regained traction inside the tumor microenvironment. By engineering TILs to express a regulatable membrane-bound IL-15 signal, amsoki-cel aims to support persistence, proliferation and cytotoxic function without forcing dependence on systemic IL-2.
Why the IL-15 design may matter in refractory disease
Interleukin-15 is a logical cytokine for adoptive cellular therapy because it supports T-cell survival and expansion while avoiding some of the broader toxicities associated with IL-2. Anchoring that signal to the membrane and making it acetazolamide-regulatable adds another layer of control. In theory, the construct allows investigators to tune T-cell fitness after infusion instead of relying on a fixed, one-size-fits-all cytokine exposure. In practice, that could translate into a better balance between tumor control and toxicity, especially in patients who have already received multiple prior lines of therapy.
The brain metastasis event from the first treated patient also offers a reminder about the anatomy of response. A strong immune attack in a previously treated lesion is not always easy to distinguish from treatment-related inflammation, and local edema can be dangerous before any durable tumor control is apparent. For melanoma patients with central nervous system involvement, the immune system’s speed can be both the therapeutic asset and the immediate threat.
What the pooled analysis can and cannot prove
This is still an early-stage signal, not a definitive practice-changing dataset. Both studies were single-arm, and the pooled analysis combined first-in-human and multicenter experience rather than comparing amsoki-cel against an active control. The Key Efficacy Set was small, and the confidence interval around the response rate remains wide. Those constraints limit how far the findings can be generalized beyond carefully selected patients who were able to receive lymphodepletion and cellular infusion.
Even so, the consistency of the safety findings after dose modification, along with the degree of early tumor shrinkage, supports continued development of the platform. The ongoing separate phase 2 pivotal Agni-01 cohort will matter because it must show whether the early response signal holds in a larger population at the recommended dose and whether the regimen remains manageable outside the most controlled early-study conditions. For now, amsoki-cel has established a plausible balance of biologic activity and tolerability in a disease area where the therapeutic gap after checkpoint failure remains wide.
ClinicalTrials.gov lists the studies under NCT05470283 and NCT06060613.